Table 1. Characteristics of Bacteremic and Non-bacteremic Subjects at Fever Visit 1.
| Fever Type at Visit 1 | 1st Fever Visit: | 1st Fever Visit: | 1st Fever Visit: | ||||||
| All patients | History of Fever | Documented Fever | |||||||
| Patient | Fever at Enrollment | Bacteremia | Bacteremia | Bacteremia | |||||
| Characteristic | All | By History | Documented | ||||||
| (n [%] or median | patients | T <37.5°C | T ≥37.5°C | No | Yes | No | Yes | No | Yes |
| [IQR]) | (n = 258) | (n = 88) | (n = 170) | (n = 219) | (n = 39) | (n = 81) | (n = 7) | (n = 138) | (n = 32) |
| Site: | |||||||||
| Coalane | 77 (29.8) | 23 (26.1) | 54 (31.8) | 63 (28.8) | 14 (35.9) | 19 (23.5) | 4 (57.1) | 44 (31.9) | 10 (31.3) |
| Inhassunge | 94 (36.4) | 37 (42.1) | 57 (33.5) | 85 (38.8) | 9 (23.1) | 35 (43.2) | 2 (28.6) | 50 (36.2) | 7 (21.9) |
| Namacurra | 87 (33.7) | 28 (31.8) | 59 (34.7) | 71 (32.4) | 16 (41.0) | 27 (33.3) | 1 (14.3) | 44 (31.9) | 15 (46.9) |
| Sex,pregnancy | |||||||||
| Fem, Pregnant | 11 (4.3) | 6 (6.8) | 5 (2.9) | 10 (4.6) | 1 (2.6) | 6 (7.4) | 0 | 4 (2.9) | 1 (3.1) |
| Non-pregnant | 163 (63.2) | 58 (65.9) | 105 (61.8) | 142 (64.8) | 21 (53.9) | 54 (66.7) | 4 (57.1) | 88 (63.8) | 17 (53.1) |
| Male | 84 (32.6) | 24 (27.3) | 60 (35.3) | 67 (30.6) | 17 (43.6) | 21 (25.9) | 3 (42.9) | 46 (33.3) | 14 (43.8) |
| Age (years) | 30 (25,38) | 32 (25, 38) | 30 (26, 38) | 30 (25,38) | 30 (26, 37) | 32 (25, 38) | 35 (24, 45) | 30 (25, 38) | 30 (26, 36) |
| CD4 (cells/μL) * | |||||||||
| <50 | 26 (10.1) | 5 (5.7) | 21 (12.4) | 17 (7.8) | 9 (23.1) | 4 (4.9) | 1 (14.3) | 13 (9.4) | 8 (25.0) |
| 50–99 | 24 (9.3) | 6 (6.8) | 18 (10.6) | 14 (6.4) | 10 (25.6) | 5 (6.2) | 1 (14.3) | 9 (6.5) | 9 (28.1) |
| 100–199 | 39 (15.1) | 16 (18.2) | 23 (13.5) | 34 (15.5) | 5 (12.8) | 15 (18.5) | 1 (14.3) | 19 (13.8) | 4 (12.5) |
| 200–349 | 37 (14.3) | 11 (12.5) | 26 (15.3) | 35 (16.0) | 2 (5.1) | 10 (12.4) | 1 (14.3) | 25 (18.1) | 1 (3.1) |
| 350–499 | 30 (11.6) | 17 (19.3) | 13 (7.8) | 26 (11.9) | 4 (10.3) | 16 (19.8) | 1 (14.3) | 10 (7.3) | 3 (9.4) |
| ≥500 | 37 (14.3) | 12 (13.6) | 25 (14.7) | 34 (15.5) | 3 (7.7) | 12 (14.8) | 0 | 22 (15.9) | 3 (9.4) |
| Missing | 65 (25.2) | 21 (23.9) | 44 (25.9) | 59 (26.9) | 6 (15.4) | 19 (23.5) | 2 (28.6) | 40 (29.0) | 4 (12.5) |
| Co-trimoxazole | |||||||||
| prophylaxis | 171 (66.3) | 69 (78.4) | 102 (60.0) | 146 (66.2) | 25 (64.1) | 65 (80.2) | 4 (57.1) | 81 (58.7) | 21 (65.6) |
| Antiretroviral | |||||||||
| therapy ** | 91 (35.3) | 31 (35.2) | 60 (35.3) | 82 (37.4) | 9 (23.1) | 30 (37.0) | 1 (14.3) | 52 (37.7) | 8 (25.0) |
| Eligible, but not | |||||||||
| on ART | 106 (41.1) | 37 (42.1) | 69 (40.6) | 84 (38.4) | 22 (56.4) | 32 (39.5) | 5 (71.4) | 52 (37.7) | 17 (53.1) |
| Axillary temp | |||||||||
| ≥38.5 °C | 52 (20.2) | N/A | 52 (30.6) | 36 (16.4) | 16 (41.0) | N/A | N/A | 36 (26.1) | 16 (50.0) |
| BMI$ (kg/m2) | 19.5 | 19.9 | 19.2 | 19.6 | 18.8 | 19.9 | 20.2 | 19.3 | 18.6 |
| (6 missing) | (17.5,21.3) | (17.9, 21.5) | (17.3, 21.2) | (17.5,21.3) | (17.5, 20.7) | (17.6, 21.5) | (18.0, 21.4) | (17.4,21.3) | (17.3, 20.4) |
| Hemoglobin | |||||||||
| <8.5 g/dL | |||||||||
| (2missing) | 55 (21.5) | 20 (23.4) | 35 (20.6) | 41 (18.9) | 14 (35.9) | 17 (21.5) | 3 (42.9) | 24 (17.4) | 11 (34.4) |
| Active | |||||||||
| tuberculosis | 30 (11.6) | 11 (12.5) | 19 (11.2) | 27 (12.3) | 3 (7.7) | 11 (13.6) | 0 | 16 (11.6) | 3 (9.4) |
| New diagnosis of | |||||||||
| Malaria | 38 (14.7) | 14 (15.9) | 24 (14.1) | 34 (15.5) | 4 (10.3) | 14 (17.3) | 0 | 20 (14.5) | 4 (12.5) |
| Oral candidiasis | 14 (5.4) | 3 (3.4) | 11 (6.5) | 8 (3.7) | 6 (15.4) | 2 (2.3) | 1 (14.3) | 6 (4.4) | 5 (15.6) |
| Esophageal | |||||||||
| candidiasis | |||||||||
| (presumed) | 7 (2.7) | 1 (1.1) | 6 (3.5) | 7 (3.2) | 0 | 1 (1.2) | 0 | 6 (4.4) | 0 |
| Herpes zoster | 7 (2.7) | 2 (2.3) | 5 (2.9( | 7 (3.2) | 0 | 2 (2.5) | 0 | 5 (3.6) | 0 |
| Cough | 178 (69.0) | 59 (67.1) | 119 (70.0) | 148 (67.6) | 30 (76.9) | 54 (66.7) | 5 (71.4) | 94 (68.1) | 25 (78.1) |
| Any upper | |||||||||
| respiratory | |||||||||
| symptom | 181 (70.2) | 66 (75.0) | 115 (67.7) | 151 (69.0) | 30 (76.9) | 59 (72.8) | 7 (100) | 92 (66.7) | 23 (71.9) |
| Any lower | |||||||||
| respiratory | |||||||||
| symptom | 172 (66.7) | 62 (70.5) | 110 (64.7) | 146 (66.7) | 26 (66.7) | 57 (70.4) | 5 (71.4) | 89 (64.5) | 21 (65.6) |
| Any | |||||||||
| gastrointestinal | |||||||||
| symptom | 155 (60.1) | 53 (60.2) | 102 (60.0) | 129 (58.9) | 26 (66.7) | 48 (59.3) | 5 (71.4) | 81 (58.7) | 21 (65.6) |
| Any genitourinary | |||||||||
| symptom | 56 (21.7) | 19 (21.6) | 37 (21.8) | 46 (21.0) | 10 (25.6) | 19 (23.5) | 0 | 27 (19.6) | 10 (31.3) |
| Headache | 214 (83.0) | 71 (80.7) | 143 (84.1) | 177 (80.8) | 37 (94.9) | 64 (79.0) | 7 (100) | 113 (81.9) | 30 (93.8) |
Measurements represent a CD4 drawn ≤6 months prior to enrollment, or after enrollment if no previous CD4. 128 patients had no reported CD4 count result in the 6 months prior to study enrollment. For patients lacking recent pre-study CD4 results, we used the first CD4 drawn after enrollment when available. 65 patients had no CD4 result from either time period.
Excludes patients on 1 or 2-drug regimens for prevention of mother to child transmission (PMTCT).
$BMI = Body Mass Index.